Drug trials indicate a future of slowing the effects of Alzheimer’s
“Scientists expressed a new sense of confidence that Alzheimer’s disease can be slowed or halted, at the 18th International Conference on Alzheimer’s and Parkinson’s Disease’s.” alzforum.org overview written by Judy King
The 18th International Conference on Alzheimer’s and Parkinson’s Disease’s was held March 5th thru 9th in Lisbon, Portugal. Rooms were packed to capacity to hear 692 onsite talks or forums with Scientists expressing a new sense of confidence that Alzheimer’s disease can be slowed or halted. With the amyloid immunotherapies they currently have, they are looking to how they can be improved and in what direction the field of study goes.
Researchers at the conference reached an agreement that they should focus on exploring more disease mechanisms and developing combination therapies. They held various sessions to delve into the newest findings in tau biology, inflammation, and vascular research. Special discussions called symposia highlighted resilience mechanisms and prevention strategies like lifestyle changes, along with advancements in biomarkers. Specifically for Parkinson’s disease and other neurodegenerative protein-related conditions, presenters shared encouraging results from studies done in labs before human trials and updates on biomarker research.
During the Conference, the U.S. Food and Drug Administration announced it would convene an advisory committee to consider Lilly’s application for traditional approval for its plaque-targeting antibody “donanemab”. This is the same procedure that was followed for “Aduhelm” and “Leqembi” and is not considered a setback.
Author note: Once again it is suggested that early testing is key in effecting a change. The less change the brain has undergone, the more effective the treatment. The effects are greater seen in a person who is in the beginning stages of cognitive decline.
Article excerpt: “Data from these programs have convinced many researchers that anti-amyloid antibodies will hold a key role in treating AD. “Immunotherapies will be widely used,” Barker of the DDF predicted, adding, “We’re already thinking about how to position new drugs in combination with them.” At the same time, some people will not be able to take these drugs, due to having high vascular amyloid or other contraindications. “Amyloid immunotherapy is not for every patient,” Scheltens cautioned.—Madolyn Bowman Rogers
To read the full article published by ALZFORUM please visit this link:
Series - AD/PD ™ 2024: Advances in Science and Therapy:
Part 1 of 1 Fast Plaque clearance with little ARIA? So Teases Trontinemab at AD//PD 2024
